Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
about
Metastatic disease from uveal melanoma: treatment options and future prospectsTargeting MAPK Signaling in Age-Related Macular DegenerationSignaling Pathways in Thyroid Cancer and Their Therapeutic ImplicationsNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaA survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activitiesMEK and PI3K inhibition in solid tumors: rationale and evidence to dateRecent advances in the treatment of melanoma with BRAF and MEK inhibitorsTrametinib: a MEK inhibitor for management of metastatic melanomaIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaMolecular landscape of pancreatic cancer: implications for current clinical trialsMEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivoCIViC databaseTargeting the RAS oncogene.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Beyond RAS and BRAF: a target rich disease that is ripe for pickingRAS and BRAF in metastatic colorectal cancer managementMEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinibHigh-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsNew developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapyClinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM studyMelanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasEnhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.MEK and the inhibitors: from bench to bedside.Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumoursManagement of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Targeted therapy in sarcomas other than GIST tumorsEvaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.The Ras-Erk-ETS-Signaling Pathway Is a Drug Target for Longevity.MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporterMEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
P2860
Q26738377-E764C694-75D1-4232-8B9F-EBBC5EC789D2Q26744185-1393DC40-91F4-43A4-A05B-265868B05150Q26764899-89029C46-FFDD-4FCE-A80A-F7256209607BQ26772015-5D408B03-8E0B-4DBF-9E20-6C5DAFFFDA19Q26774752-6FA6FA09-20A7-44B8-B67C-5F8FAC6C6064Q26775573-DEA8F7C4-4995-4582-BD7E-F1FC6AD2C6FEQ26778769-E113519C-9E39-49BE-A78C-6B6D40D374D3Q26782976-8E8EA523-440B-4C2D-A669-609AC7345025Q26824310-7B91658E-1A15-4202-81D8-2D07CC46CAEDQ26824528-5DB93BA2-345F-4162-84C6-84FE1D45A67AQ27335195-2104E5E3-0654-4CA9-915E-26428CDD8631Q27612411-535CDAED-3EB4-4EFE-B0E2-B9CEEA02B4BCQ27687198-7AC48888-F6FE-4608-B1B1-CFE3510262FDQ27853216-2DE3C51D-E149-467A-82E7-E9F832684D71Q28066095-4D7EE85A-13C5-4D2A-A3D6-74B15743F043Q28074175-666ACD8D-5359-41C0-966A-211BB29A8D52Q30278995-D2AE7AFA-DAA3-46E7-99DC-116498BC0DB0Q30422319-3BD9AA2A-CBEA-42DE-891F-E07F35B0DF73Q30847302-AE192515-8DE1-4D04-A811-14A5E84EF34FQ33408049-2C4E96AB-C983-488B-B8F3-0D3B6E92C890Q33441341-4DE36504-2330-49AB-A1CC-147BEC3256C1Q33756991-EFA81844-FFF5-4C9E-ACB4-1E7D50843A65Q33824552-CC550D21-D7E3-4DD0-B423-7AB964B93D0CQ33830941-2906C134-ABDF-4C52-AAF1-29DE035BA10EQ33845387-F5F5EE12-CE9A-435C-A578-95F82ADF4A05Q33900906-28564CDD-5F1F-44B9-B378-913A468B9212Q33971120-ADE8A824-76B8-4041-9D2D-96878371AA8AQ34036341-E9CBA9B1-4E66-4743-AB69-AFF4836CB725Q34532980-88112378-CDFC-49E6-B6BE-AA2FCB75D06EQ34571039-F1037AEA-1465-4D3B-B836-1BBE11F8FCC0Q35136819-ABE6781B-A5B5-4EDE-967B-2BBBF1BCD231Q35376207-D49A619B-E646-462E-9E9B-FEC9B30B3F28Q35566045-45D182E6-1123-4643-A9E7-1FA1CC69C373Q35586700-503D19E4-B4DC-4996-AC10-CBD8EBE3214BQ35622367-3A8C2C57-7517-49CC-835E-64209BDA8B83Q35675442-E2CCB7C9-6BB9-4AB9-9472-84480C50FE08Q35898911-2086D3C1-E6CD-4704-B7A5-4B6000FD6ADEQ35970072-975F21CE-6BDB-4965-8CEB-1F7F614ED21CQ36021057-E6741513-E381-4C86-A259-277F44CAB56DQ36328021-062DF117-33E2-4DCD-9098-436DA8D7A0DA
P2860
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@ast
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@en
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@nl
type
label
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@ast
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@en
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@nl
prefLabel
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@ast
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@en
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@nl
P2093
P921
P3181
P1433
P1476
Safety, pharmacokinetic, pharm ...... phase 1 dose-escalation trial.
@en
P2093
Carlos Becerra
Donna S Cox
Douglas J DeMarini
Gail Eckhardt
Gerald S Falchook
Howard A Burris
Jeffrey R Infante
Johanna C Bendell
Leslie A Fecher
Lowell Hart
P304
P3181
P356
10.1016/S1470-2045(12)70270-X
P577
2012-08-01T00:00:00Z